Endocrine Abstracts

Pheochromocytomas and paragangliomas (PPGL) are commonly benign catecholamine-producing neuroendocrine tumors (NETs); however, up to 25 % of patients develop distant metastases or aggressive behavior. The current classification of PPGL comprises pseudohypoxia-profile, MAPK-pathway alteration, and Wnt-pathway dysregulation clusters according to their genomic characterization. However, to date, there are no biomarkers to help stratify patients based on their prognosis. Alternati...

Glioblastoma (GBM; grade IV astrocytoma) is the one of the most malignant and lethal endocrine-related cancers worldwide. Current standard treatment consists of surgery followed by radiotherapy and/or chemotherapy; however, this is only a palliative approach with a mean post-operative survival of scarcely ~12-15 months. Therefore, the identification of novel therapeutic targets to treat this devastating pathology is urgently needed. In this context, the truncated splicing-vari...

Lung neuroendocrine neoplasms (LungNENs) are highly heterogeneous tumors, which are classified by the WHO according to their histological grade into low grade: Typical Carcinoids (TC) and intermediate grade Atypical Carcinoids (AC), and high-grade: Large Cell Neuroendocrine Carcinoma (LCNEC) and Small Cell Lung Cancer (SCLC). Recently, a number of studies have tried to untangle the molecular features that define each subtype by applying different approaches, including genomic,...

Neuroendocrine tumors (NETs) represent a heterogeneous group of malignancies with increasing incidence worldwide, due in part to enhanced awareness and diagnosis improvements. Surgery is often effective for local disease, whereas disseminated or metastatic disease require pharmacological treatment, which is not always successful. Pancreatic (Pan-NETs) and pulmonary (Lung-NETs) neuroendocrine tumors frequently express somatostatin receptors (SSTs), providing the target for trea...

Lung neuroendocrine neoplasms (LungNENs) comprise a diverse group of rare tumors with a commonly difficult and late diagnosis, which often require complex management and treatment. The most frequently mutated genes in LungNENs have recently been identified, including known components of the chromatin-regulating pathways such as MEN1, PSIP1 and ARID1A, which are the subject of ongoing detailed studies. In contrast, other key regulatory mechanisms, par...

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) that arise in the adrenal medulla and paraganglia, respectively. As occurs in the rest of NENs, PPGLs commonly present a high density of somatostatin receptors (SSTs) on their membrane. However, unlike in most NENs, somatostatin analogues (SSAs) do not represent a suitable therapeutic target in PPGLs, and the mechanisms underlying this mismatch are still unclear. In this study, we aim to iden...

Pheochromocytomas and paragangliomas (PPGL) are infrequent neuroendocrine neoplasms, which develop metastases or aggressive behaviour in 25 % patients. They can be classified into three clusters according to their molecular features; nevertheless, these differences may not stratify patients according to their prognosis. The dysregulation of the splicing process has emerged as a novel feature shared by most cancers, which is associated with an aggressive phenotype in several tu...

: Hepatic steatosis is a common obesity-associated pathology characterized by the accumulation of fat within the liver, which can progress to liver fibrosis, cirrhosis and ultimately lead to hepatocellular carcinoma. Remarkably, obesity and cancer course with a profound dysregulation of the genetic expression patterns and, particularly, with the aberrant expression of splicing variants that could contribute to the aggressiveness and comorbidities of these pathologies. Since th...

Pituitary adenomas (PA) comprise a commonly underestimated pathology in terms of incidence and associated morbimortality. To date, somatostatin and dopamine analogs represent the main medical treatment, but an appreciable subset of patients are resistant or poorly responsive to these drugs. Therefore, the search for new approaches to control tumor growth and/or hormone secretion is crucial. Biguanides such as metformin (MF; commonly used to treat type-2 diabetes), phenformin (...

Pituitary adenomas (PA) comprise a commonly underestimated pathology in terms of incidence and associated morbi-mortality. Although somatostatin analogs and dopamine antagonists constitute the main medical treatments for PAs, an appreciable subset of patients are resistant or poorly responsive to these drugs and hence is crucial the search for new therapies. Biguanides such as metformin (MF; commonly used to treat type-2 diabetes), phenformin (PF) and buformin (BF) have been s...